| 000 | 01644 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250515025438.0 | ||
| 264 | 0 | _c20060713 | |
| 008 | 200607s 0 0 eng d | ||
| 022 | _a0007-0920 | ||
| 024 | 7 |
_a10.1038/sj.bjc.6603132 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYeow, W-S | |
| 245 | 0 | 0 |
_aPotentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. _h[electronic resource] |
| 260 |
_bBritish journal of cancer _cMay 2006 |
||
| 300 |
_a1436-45 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, N.I.H., Intramural | ||
| 650 | 0 | 4 |
_aAnticonvulsants _xpharmacology |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 |
_aApoptosis _xdrug effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Synergism |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xpharmacology |
| 650 | 0 | 4 | _aHistone Deacetylase Inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNF-kappa B _xgenetics |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aStaurosporine _xanalogs & derivatives |
| 650 | 0 | 4 | _aTumor Cells, Cultured |
| 650 | 0 | 4 |
_aValproic Acid _xpharmacology |
| 700 | 1 | _aZiauddin, M F | |
| 700 | 1 | _aMaxhimer, J B | |
| 700 | 1 | _aShamimi-Noori, S | |
| 700 | 1 | _aBaras, A | |
| 700 | 1 | _aChua, A | |
| 700 | 1 | _aSchrump, D S | |
| 700 | 1 | _aNguyen, D M | |
| 773 | 0 |
_tBritish journal of cancer _gvol. 94 _gno. 10 _gp. 1436-45 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/sj.bjc.6603132 _zAvailable from publisher's website |
| 999 |
_c16304796 _d16304796 |
||